PROCEPT BioRobotics Corporation Stock

Equities

PRCT

US74276L1052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
61.74 USD +1.86% Intraday chart for PROCEPT BioRobotics Corporation +18.09% +47.32%
Sales 2024 * 213M Sales 2025 * 299M Capitalization 3.17B
Net income 2024 * -101M Net income 2025 * -71M EV / Sales 2024 * 14.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 10.6 x
P/E ratio 2024 *
-31.2 x
P/E ratio 2025 *
-44.2 x
Employees 626
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.43%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PROCEPT BioRobotics Corporation

1 day+1.86%
1 week+18.09%
Current month+16.53%
1 month+32.60%
3 months+28.87%
6 months+89.33%
Current year+47.32%
More quotes
1 week
51.53
Extreme 51.53
63.26
1 month
45.56
Extreme 45.56
63.26
Current year
39.48
Extreme 39.48
63.26
1 year
24.83
Extreme 24.83
63.26
3 years
15.38
Extreme 15.38
63.26
5 years
15.38
Extreme 15.38
63.26
10 years
15.38
Extreme 15.38
63.26
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 20-02-05
Director of Finance/CFO 46 -
Chief Tech/Sci/R&D Officer - 16-05-31
Members of the board TitleAgeSince
Chairman 72 11-07-31
Director/Board Member 48 20-12-16
Chief Executive Officer 69 20-02-05
More insiders
Date Price Change Volume
24-05-02 61.74 +1.86% 1,020,737
24-05-01 60.61 +14.40% 2,129,587
24-04-30 52.98 +1.79% 875,721
24-04-29 52.05 +0.42% 593,649
24-04-26 51.83 -0.86% 586,484

Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT

More quotes
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
61.74 USD
Average target price
60.83 USD
Spread / Average Target
-1.47%
Consensus